Article info
PDFSection 4: Clinical pharmacy services
4CPS-314 3 day course of low dose subcutaneous anakinra in patients with refractory moderate–severe COVID-19: a proof-of-concept study
Citation
4CPS-314 3 day course of low dose subcutaneous anakinra in patients with refractory moderate–severe COVID-19: a proof-of-concept study
Publication history
- First published March 14, 2021.
Online issue publication
March 15, 2021
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.